| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | May 14, 2025 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Apr 30, 2025 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Total Haloacetic Acids (HAA5) | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| TTHM | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| LASSO | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| LASSO | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| BHC-GAMMA | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| BHC-GAMMA | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Chlordane | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Heptachlor epoxide | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Heptachlor | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Heptachlor | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| HEXACHLOROBENZENE | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| HEXACHLOROBENZENE | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Benzo(a)pyrene | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Atrazine | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | Cardiovascular system or reproductive problems |
| Endrin | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Endrin | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Methoxychlor | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Methoxychlor | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Toxaphene | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Toxaphene | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Di(2-ethylhexyl) adipate | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Di(2-ethylhexyl) adipate | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Simazine | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Simazine | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Di(2-ethylhexyl) phthalate | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Di(2-ethylhexyl) phthalate | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Hexachlorocyclopentadiene | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Hexachlorocyclopentadiene | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Atrazine | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | Cardiovascular system or reproductive problems |
| Heptachlor epoxide | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Chlordane | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| Benzo(a)pyrene | Monitoring | N/A | N/A | Sep 30, 2024 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Jul 31, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jul 31, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Jul 31, 2024 | Resolved | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jul 1, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jul 1, 2024 | Resolved | N/A |
| Hexachlorocyclopentadiene | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Hexachlorocyclopentadiene | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Endrin | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Endrin | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Simazine | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Simazine | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Heptachlor | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Heptachlor | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Methoxychlor | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Methoxychlor | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Atrazine | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Cardiovascular system or reproductive problems |
| Atrazine | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | Cardiovascular system or reproductive problems |
| HEXACHLOROBENZENE | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Heptachlor epoxide | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| BHC-GAMMA | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Toxaphene | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Di(2-ethylhexyl) phthalate | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| LASSO | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| HEXACHLOROBENZENE | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Chlordane | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Chlordane | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Benzo(a)pyrene | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Benzo(a)pyrene | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Heptachlor epoxide | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| LASSO | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Di(2-ethylhexyl) adipate | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Toxaphene | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Di(2-ethylhexyl) adipate | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Di(2-ethylhexyl) phthalate | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| BHC-GAMMA | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 16, 2024 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Feb 16, 2024 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.015 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.015 | Jun 30, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Di(2-ethylhexyl) adipate | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Atrazine | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | Cardiovascular system or reproductive problems |
| Toxaphene | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Toxaphene | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Di(2-ethylhexyl) adipate | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Di(2-ethylhexyl) adipate | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Simazine | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Di(2-ethylhexyl) adipate | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| HEXACHLOROBENZENE | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| HEXACHLOROBENZENE | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| HEXACHLOROBENZENE | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| HEXACHLOROBENZENE | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Toxaphene | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Di(2-ethylhexyl) phthalate | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Di(2-ethylhexyl) phthalate | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Di(2-ethylhexyl) phthalate | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Di(2-ethylhexyl) phthalate | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Simazine | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Heptachlor | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Heptachlor | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Heptachlor | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Heptachlor | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Heptachlor epoxide | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Heptachlor epoxide | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Heptachlor epoxide | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Heptachlor epoxide | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Simazine | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Simazine | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| BHC-GAMMA | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| BHC-GAMMA | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| BHC-GAMMA | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| BHC-GAMMA | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Atrazine | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | Cardiovascular system or reproductive problems |
| Atrazine | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | Cardiovascular system or reproductive problems |
| Atrazine | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | Cardiovascular system or reproductive problems |
| Toxaphene | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Methoxychlor | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Methoxychlor | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Methoxychlor | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Methoxychlor | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| LASSO | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| LASSO | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| LASSO | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| LASSO | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Benzo(a)pyrene | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Benzo(a)pyrene | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Benzo(a)pyrene | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Benzo(a)pyrene | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Pentachlorophenol | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Chlordane | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Chlordane | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Chlordane | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Chlordane | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Endrin | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Endrin | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Endrin | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Hexachlorocyclopentadiene | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Hexachlorocyclopentadiene | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Hexachlorocyclopentadiene | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Hexachlorocyclopentadiene | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Endrin | Monitoring | N/A | N/A | Jun 30, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.02 | Mar 31, 2023 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.027 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Dec 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.027 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.027 | Sep 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.026 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.026 | Jun 30, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jun 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.023 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.023 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.023 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.023 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.023 | Mar 31, 2022 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 20, 2022 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Mar 20, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Feb 28, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Jan 31, 2022 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.018 | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Nov 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Oct 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.014 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.014 | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2021 | Resolved | N/A |
| Lead and Copper Rule | Monitoring | N/A | N/A | Sep 28, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Aug 31, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 22, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Aug 22, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 21, 2021 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 21, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | May 31, 2021 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.016 | Mar 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Feb 24, 2021 | Resolved | N/A |